Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 104232434 | 10423243 | 4 | F | 20050818 | 20160913 | 20140902 | 20160929 | PER | US-JNJFOC-20140827123 | JANSSEN | 6.97 | YR | C | M | Y | 0.00000 | 20160929 | CN | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 104232434 | 10423243 | 1 | SS | RISPERDAL | RISPERIDONE | 1 | Oral | N | U | 0 | SOLUTION | ||||||||
| 104232434 | 10423243 | 2 | SS | RISPERDAL | RISPERIDONE | 1 | Oral | N | U | 0 | SOLUTION | ||||||||
| 104232434 | 10423243 | 3 | PS | RISPERDAL | RISPERIDONE | 1 | Oral | N | U | 20588 | SOLUTION | ||||||||
| 104232434 | 10423243 | 4 | SS | INVEGA | PALIPERIDONE | 1 | Oral | U | U | 0 | OROS (ORAL OSMOTIC) THERAPEUTIC SYSTEM TABLET | ||||||||
| 104232434 | 10423243 | 5 | SS | INVEGA | PALIPERIDONE | 1 | Oral | U | U | 0 | OROS (ORAL OSMOTIC) THERAPEUTIC SYSTEM TABLET | ||||||||
| 104232434 | 10423243 | 6 | SS | INVEGA | PALIPERIDONE | 1 | Oral | U | U | 21999 | OROS (ORAL OSMOTIC) THERAPEUTIC SYSTEM TABLET | ||||||||
| 104232434 | 10423243 | 7 | SS | RISPERIDONE. | RISPERIDONE | 1 | Oral | U | 0 | TABLET | |||||||||
| 104232434 | 10423243 | 8 | C | ABILIFY | ARIPIPRAZOLE | 1 | Unknown | D | 0 | UNSPECIFIED |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 104232434 | 10423243 | 1 | Aggression |
| 104232434 | 10423243 | 2 | Attention deficit/hyperactivity disorder |
| 104232434 | 10423243 | 3 | Autism spectrum disorder |
| 104232434 | 10423243 | 4 | Aggression |
| 104232434 | 10423243 | 5 | Attention deficit/hyperactivity disorder |
| 104232434 | 10423243 | 6 | Autism spectrum disorder |
| 104232434 | 10423243 | 7 | Product used for unknown indication |
| 104232434 | 10423243 | 8 | Product used for unknown indication |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 104232434 | 10423243 | HO |
| 104232434 | 10423243 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 104232434 | 10423243 | Galactorrhoea | |
| 104232434 | 10423243 | Gynaecomastia | |
| 104232434 | 10423243 | Hyperlipidaemia | |
| 104232434 | 10423243 | Hyperprolactinaemia | |
| 104232434 | 10423243 | Obesity |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |